Know Cancer

or
forgot password

Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)


Phase 2
20 Years
74 Years
Not Enrolling
Both
Gastrointestinal Stromal Tumors

Thank you

Trial Information

Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)


Inclusion Criteria:



- Patients who completed the CSTI571B1201 study

Exclusion Criteria:

-

Other protocol-defined inclusion / exclusion criteria may apply.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To study the antineoplastic effect of the investigational drug.

Principal Investigator

Novartis Pharmaceuticals

Investigator Role:

Study Director

Investigator Affiliation:

Novartis Pharmaceuticals

Authority:

Japan: Ministry of Health, Labor and Welfare

Study ID:

CSTI571B1202

NCT ID:

NCT00237172

Start Date:

September 2002

Completion Date:

Related Keywords:

  • Gastrointestinal Stromal Tumors
  • GIST
  • Imatinib
  • STI571
  • Gastrointestinal Stromal Tumors
  • Gastrointestinal Stromal Tumors

Name

Location